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Abstract
Background
Schistosomiasis, a severe disease caused by parasites of the genus Schistosoma, is preva-
lent in 74 countries, affecting more than 250 million people, particularly children. We have
previously shown that the Schistosoma mansoni gut-derived cysteine peptidase, cathepsin
B1 (SmCB1), administered without adjuvant, elicits protection (>60%) against challenge
infection of S. mansoni or S. haematobium in outbred, CD-1 mice. Here we compare the
immunogenicity and protective potential of another gut-derived cysteine peptidase, S. man-
soni cathepsin L3 (SmCL3), alone, and in combination with SmCB1. We also examined
whether protective responses could be boosted by including a third non-peptidase schisto-
some secreted molecule, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH), with the
two peptidases.
Methodology/Principal findings
While adjuvant-free SmCB1 and SmCL3 induced type 2 polarized responses in CD-1 outbred
mice those elicited by SmCL3 were far weaker than those induced by SmCB1. Nevertheless,
both cysteine peptidases evoked highly significant (P < 0.005) reduction in challenge worm
burden (54–65%) as well as worm egg counts and viability. A combination of SmCL3 and
SmCB1 did not induce significantly stronger immune responses or higher protection than that
achieved using each peptidase alone. However, when the two peptidases were combined
with SG3PDH the levels of protection against challenge S. mansoni infection reached 70–
76% and were accompanied by highly significant (P < 0.005) decreases in worm egg counts
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and viability. Similarly, high levels of protection were achieved in hamsters immunized with
the cysteine peptidase/SG3PDH-based vaccine.
Conclusions/Significance
Gut-derived cysteine peptidases are highly protective against schistosome challenge infection
when administered subcutaneously without adjuvant to outbred CD-1 mice and hamsters, and
can also act to enhance the efficacy of other schistosome antigens, such as SG3PDH. This
cysteine peptidase-based vaccine should now be advanced to experiments in non-human pri-
mates and, if shown promise, progressed to Phase 1 safety trials in humans.
Author summary
Schistosomiasis, a severe disease caused by parasites of the genus Schistosoma, is prevalent
in 74 countries in the Middle-east, Africa, South America and South-East Asia, and affects
more than 250 million people, particularly children. Praziquantel is the most effective
anti-schistosome drug and is the mainstay of mass drug administration (MDA) programs.
However, concerns about the emergence of drug-resistant parasites or reduced efficacy
have highlighted the urgent need for an efficacious vaccine that could interfere with para-
site establishment and transmission. Here we examine the immunogenicity and vaccine
potential of functionally active recombinant forms of the gut-derived cysteine peptidases
of S. mansoni, cathepsin B1 (SmCB1) and cathepsin L3 (SmCL3), alone, or in combina-
tion. We demonstrate their capacity to induce high levels (>60%) of protection without
the need of adjuvant against challenge infection with S. mansoni cercariae. A vaccine that
combined SmCB1 and SmCL3 with another secreted molecule, S. mansoni glyceraldehyde
3-phosphate dehydrogenase (SG3PDH), induces predominant type 2 immune responses,
and consistently evokes superior protection (>70%) against S. mansoni challenge infec-
tion in both outbred CD-1 mice and hamsters. This efficacious adjuvant-free cysteine pep-
tidase-based vaccine should be brought forward into trials in non-human primates for
assessment as a prospective vaccine against human schistosomiasis.
Introduction
Schistosomiasis is caused by infection with helminth parasites of the genus Schistosoma. It is a
water-borne debilitating disease that prevails in 74 developing countries of the Middle East,
sub-Saharan Africa, and South America, and infects >250 million people. The infective stage,
the cercaria, is shed by freshwater snails in large numbers and infects their human host by pen-
etration of the skin. The parasites migrate via the blood to the lungs and then the liver before
finally settling as male and female worms in the mesenteric (Schistosoma mansoni, S. japoni-
cum) and bladder venules (S. haematobium). Schistosomiasis infects mainly rural populations,
particularly children while they bath and play in freshwater tributaries [1]. Infection proceeds
relatively unnoticed until eggs released by fecund females and destined to leave via the intes-
tine or bladder, instead become trapped in the liver, gastrointestinal tract, or urinary bladder
tissues. Here they induce potent inflammatory responses that lead to the development of
severe granulomatous inflammation and fibrosis in the liver or bladder. In children, symptoms
include anemia, abdominal pain and diarrhea, as well as growth and cognitive impairments
[1–3].
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Praziquantel is the only drug readily available for the treatment of schistosomiasis and
because of its low cost, safety and efficacy has been the principal means of intervention to con-
trol schistosomiasis through mass drug administration (MDA) programs. Treatment with pra-
ziquantel, however, only reaches ~13% of the target population and because of the large pill
size and bitterness it is generally not recommended for children below 6 years of age [4]. Fur-
thermore, praziquantel does not prevent reinfection, therefore requiring repeated treatment,
and has reduced efficacy in people with heavy infections [3,4]. There are fears surrounding the
potential for the emergence of drug-resistant parasites [3] and a recent report from an MDA
program in Uganda suggests that high exposure to the drug may reduce its effectiveness [5].
An efficacious and safe vaccine administered to young children would prevent infection
and diminish transmission, as well as increase the likelihood of parasite elimination [1–3].
However, to date, only a few antigens have been advanced to Phase 1 trials in humans, includ-
ing Sm-TSP-2 and Sm-14 for S. mansoni and Sh28GST (Bilhvax) for S. haematobium, while
only one other, Smp80, is undergoing trials in non-human primates [3, 6–9]. The dearth of
vaccines in the pipeline is worrying and therefore a major effort is required to employ new
ways of discovering, shortlisting and delivering vaccine candidates.
Our research has focused on the identification of vaccine molecules in the parasite excre-
tory-secretory products (ESP) because these are involved in host-parasite interaction and
induce potent immune responses [10]. Contrary to cytosolic and surface membrane antigens,
we reasoned that these were more accessible to attack by antibodies and activated immune
effector cells [10]. We recently demonstrated that candidate vaccines in ESP formulated in the
presence of the type 2 cytokines, thymic stromal lymphopoietin (TSLP), interleukin (IL)-25 or
IL-33, induced considerably high protection in mice, in the range of 50% - 75%, against a chal-
lenge infection of S. mansoni cercariae [11]. We also discovered that a similar level of protec-
tion could be achieved by delivering antigens with the cysteine peptidase, papain, which also
induces type 2 immune responses [11–13]. To avoid employing a plant-derived peptidase,
we then showed that the gut-derived papain-like cysteine peptidases of Schistosoma mansoni,
cathepsin B1 (SmCB1), and Fasciola hepatica, cathepsin L1 (FhCL1), could induce predomi-
nant type 2 immune responses and highly significant (P< 0.005) reduction of between 66%
and 75% in challenge S. mansoni and S. haematobium worm burden and worm egg counts of
outbred mice and hamsters [12, 14, 15].
The objectives of the present study were to compare and contrast the immunogenicity
and protective potential of SmCB1 with another gut-derived schistosome cysteine peptidase,
SmCL3 [16], alone and in combination in CD-1 outbred mice. We report that functionally
active recombinant SmCB1 and SmCL3-based vaccine administered subcutaneously induces
highly significant (P< 0.002) protection of> 60% against S. mansoni challenge infection in
both mice and hamsters. A vaccine combining SmCB1 and SmCL3 with another secreted
molecule, S. mansoni glyceraldehyde 3-phosphate dehydrogenase (SG3PDH), which is also
located at the host-parasite interface [17–19], elicited impressive levels (>70%) of protection
to S. mansoni challenge infection suggesting that this efficacious trivalent vaccine should now
be brought forward into trials in non-human primates for assessment as a potential vaccine to
control human schistosomiasis.
Materials and methods
Ethics statement
All animal experiments were performed following the recommendations of the current edition
of the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal
Resources, National Research Council, USA, and were approved by the Institutional Animal
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
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Care and Use Committee (IACUC) of the Faculty of Science, Cairo University, permit num-
bers CUFS F PHY 21 14 and CUFS-F-Imm-5-15.
Parasites and animals
Female CD-1 mice and female Syrian hamsters (Mesocricetus auratus) were bred at the Schis-
tosome Biological Materials Supply Program, Theodore Bilharz Research Institute (SBSP/
TBRI), Giza, Egypt until 6 weeks of age and then maintained throughout experimentation at
the animal facility of the Zoology Department, Faculty of Science, Cairo University. Cercariae
of an Egyptian strain of S. mansoni were obtained from SBSP/TBRI, and used immediately
after shedding from Biomphalaria alexandrina snails. CD1 mice were infected via whole body
exposure as previously described [11, 13]. Hamsters were anesthetized, the abdomen shaved
and wetted with sterile deionized water, and then exposed to cercariae via the ring method as
previously described [12].
Immunogens
Recombinant S. mansoni glyceraldehyde 3-phosphate dehydrogenase (rSG3PDH) expressed in
the bacterium Escherichia coli was prepared and purified to homogeneity [17] (S1 Fig). This
preparation contained <0.06 Endotoxin Units/ml as judged by the Pyrogen Gel-Clot Limulus
Amebocyte Lysate test. Functionally active S. mansoni cathepsin B1 (SmCB1) and cathepsin L3
(SmCL3) were produced in methyltrophic yeast Pichia pastoris GS115 (Invitrogen) and Pichia-
Pink (Thermo Fisher) strain, respectively, using methods previously described in our labora-
tory [20]. Recombinant cathepsins were purified by Ni-NTA column, desalted by dialysis, and
stored in phosphate buffered saline, pH 7.3 at -80˚C. Cathepsin peptidase purity was deter-
mined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and activity
using the fluorogenic substrate Z-Phe-Arg-NHMec (Sigma-Aldrich, UK) and PolarStar
Omega fluorescence reader (BMG Labtech) [20–22] (S1 Fig). Concentration of the purified
peptidases was evaluated using the Protein Assay Kit of BioRad.
Serum preparation
Blood samples were obtained from individual naïve, unimmunized and immunized mice (3 or
4 per group) seven days following infection with viable S. mansoni cercariae, unless stated oth-
erwise. Sera were separated and stored at -20˚C.
Isolation and culture of epidermal, lymph node and spleen cells
Epidermal cells (EC) were isolated from three mice per group two days after S. mansoni in-
fection, at the time when larvae are still resident in the epidermis, following the protocol
described by Jensen et al. [23] with minor modifications. The whole procedure was recently
detailed [13]. Lymph node cells (LNC) from inguinal and popliteal lymph nodes (LN) were
recovered (3 mice per group) four days after S. mansoni infection at the time when larvae are
in the dermis or dermal capillaries. LNC were also obtained from mice 21 days after immuni-
zation with vaccine molecules. Spleen cells (SC) were prepared from spleens removed from
three mice per group at seven and 14 days after S. mansoni infection [11, 13, 14].
EC, LNC, and SC were re-suspended in RPMI-1640 medium supplemented with 200 U/ml
penicillin, 200 μg/ml streptomycin, 25 mM HEPES, 50 ng/ml amphotericin, 5 x 10–5 M 2-mer-
captoethanol, and 5% fetal calf serum (culture medium). Twenty μg/ml polymyxin B (Sigma-
Aldrich) was added as an inhibitor of any residual lipopolysaccharide contamination of
recombinant antigens. EC, LNC and SC were cultured at a concentration of 1 x 106 cells/200 μl
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
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culture medium/well in duplicate wells of 96 round-bottomed well plates (Corning Costar,
Bedford, MA), stimulated with 0 or 20 μg/ml membrane filter (0.45 μm)-sterilized immuno-
gen, and maintained at 37˚C in a humidified atmosphere containing 3.0% CO2. After 72 h of
incubation, cultured cells were frozen and thawed for release of intracellular cytokines, the
lysate centrifuged (15,000 x g) and supernatants stored at -76˚C until assayed for cytokine con-
centrations by capture enzyme-linked immunosorbent assay (ELISA) [11, 13, 14].
Immunological assays
Mouse serum antibody titer and isotype were assessed by indirect ELISA for binding to 250
ng/well immunogen in duplicate wells [11, 13, 14]. Horseradish peroxidase (HRP)-labeled
goat anti-mouse IgG (H+L) conjugate (Promega, Madison, WI) was used to detect bound anti-
bodies. Individual sera were serially diluted to determine the antibody titer and select the
appropriate dilution for assessing the antibody isotypes. Based on these results, sera were
diluted 1:100 or 1:200 to estimate the level of IgM and IgG class antibodies, and 1:25 for IgE
and IgA antibodies. Biotin-labeled rat monoclonal antibody to mouse IgG1 (Pharmingen, San
Diego, CA), IgA, and IgE (BioLegend, San Diego, CA), was diluted 1:500 in washing buffer
(0.01 M phosphate buffered-saline, pH 7.2, 0.05% Tween 20/0.1% bovine serum albumin).
Alkaline phosphatase- (AKP) or HRP-labeled streptavidin was diluted 1:1000. Monoclonal
antibody to IgM, IgG2a and IgG2b (Pharmingen) labeled with AKP were diluted 1:500, 1:1000
and 1:1000, respectively. Reactivity was estimated spectrophotometrically after adding Sure-
Blue TMB Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories, Inc., Gaithers-
burg, MD) or p-nitro phenyl phosphate (PNPP) substrate (Calbiochem, San Diego, CA).
Release of mouse IL-1β, IL-5, IL-12, IL-17, IL-25, IFN-γ, TSLP (ELISA MAX Set, BioLe-
gend, San Diego, CA), and IL-13 (DuoSet ELISA Development System, R&D System Europe)
was measured in supernatants of duplicate cell cultures by capture ELISA, following the manu-
facturer’s instructions.
Parasitological assays
Worm burden as well as liver and intestine worm egg load in individual mice and hamsters
(5–10 animals per group) were evaluated six to seven weeks after the challenge infection
with S. mansoni cercariae [11, 13, 15]. Percent (%) change was evaluated by the formula: %
change = [mean number in unimmunized infected controls–mean number in immunized
infected animals / mean number in infected controls] × 100.
Egg developmental stages were evaluated using 3–5 fragments of the distal portion of the
ileum. After washing in 0.9% saline solution and slight drying on absorbent paper, each intesti-
nal fragment was placed between 2 slides and analyzed by light microscopy to classify the eggs.
For each fragment, up to 400 eggs were counted and classified according to their developmen-
tal stage as immature, with miracidium occupying less than two-thirds of the shell, mature
containing an already developed miracidium, and non-viable, dead, clearly calcified, opaque
[24].
Experimental design of vaccine trials
(a) Comparison of the immunogenicity and vaccine potential of SmCB1 and SmCL3 (Fig
1A). Seventy-five female CD-1 mice were divided into three groups of 25 mice each.
Mice were injected subcutaneously twice, with a three week-interval, at the tail base
region with 100 μl Dulbecco’s phosphate-buffered saline, pH 7.1 (D-PBS) alone (control
group) or containing 10 μg SmCB1 or SmCL3. Serum was obtained from three mice per
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
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group on days 7 and 21 after the second immunization. At 21 days, LNC were also
assessed for cytokine release after three-day stimulation with the immunogen.
The remaining control and immunized mice were infected with 150 cercariae of S. mansoni 3
weeks after the second immunization. EC and LNC were isolated 2 and 4 days later, respec-
tively from three mice/group, incubated with 0 or 20 μg/ml immunogen, and cell culture
supernatants assessed for the levels of released TSLP, IL-1, IL-12, IL-25. On day 7 and 14,
when a large proportion of migrating larvae are in the lung capillaries and liver sinusoids,
respectively, serum and SC from three mice/group were assessed for humoral and cytokine
responses to the immunogen. Parasitological parameters (see above) were evaluated for the
remaining 6–8 mice per group at 49 days after the challenge infection (Fig 1A).
(b) Evaluation of the immunogenicity and vaccine potential of SmCL3 alone or in combina-
tion with SmCB1 and SG3PDH (Fig 1B). Fifty-two CD-1 mice were randomly divided into 4
groups of 13 mice, and immunized subcutaneously twice, with a 3 week-interval, with 100 μl
D-PBS containing 0 (control Group 1), 10 μg SmCL3 (Group 2), 10 μg SmCL3 and 10 μg
Fig 1. Overview of vaccine schedule using SmCB1 and SmCL3 in mice. Schedule shows regime of vaccine delivery and challenge infection with
schistosome cercariae. Time-points of tissue sampling and parasitological analysis are also shown.
https://doi.org/10.1371/journal.pntd.0005443.g001
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SmCB1 administered subcutaneously on different sides of the tail (Group 3), 10 μg SmCL3
and 10 μg SmCB1 administered as above and 10 μg SG3PDH intramuscularly, to avoid imme-
diate exposure to the cysteine peptidases (Group 4). Three weeks after the second immuniza-
tion all mice were challenged with 120 cercariae of S. mansoni. Humoral and SC cytokine
responses to the immunogens at seven days after infection were assessed using three mice per
group. Parasitological parameters were evaluated for the remaining 10 mice per group at 42
days after the challenge infection (Fig 1B).
(c) Efficacy of a trivalent vaccine in mice and hamsters (Fig 2). Forty CD-1 mice were
divided into groups of 10 mice, and immunized twice, with a three–week interval, with 0
(control group), 10 μg SmCB1 + 10 μg SG3PDH, 10 μg SmCL3 + 10 μg SG3PDH, and
10 μg SmCL3 + 10 μg SmCB1 + 10 μg SG3PDH (SG3PDH was given intramuscularly).
All mice were challenged with 130 cercariae of S. mansoni two weeks after the last immu-
nization. Humoral and SC cytokine responses to the immunogens at 7 days after infec-
tion were assessed using three mice per group. Parasitological parameters were examined
for the remaining 7 mice on day 42 or 43 after challenge infection (Fig 2A).
To assess the vaccine in a different host, 40 hamsters were allocated into 4 groups of 10 ani-
mals, and immunized following a protocol similar to that described in (c) above with the
exception that these were administered 15 μg rather than 10 μg of each immunogen for both
immunizations. Five hamsters in each group were challenged 4 and 6 weeks after the last
immunization with 200 or 150 cercariae (Fig 2B), respectively. Parasitological parameters were
examined for all hamsters on day 42 or 43 after challenge infection.
Statistical analyses
All values were tested for normality. Mann–Whitney 2-tailed test was used to analyze the sta-
tistical significance of differences between experimental and control values and considered sig-
nificant at P< 0.05.
Results
Immunogenicity and protective capacity of S. mansoni cysteine
proteases cathepsin B1 (SmCB1) and cathepsin L3 (SmCL3)
We have previously demonstrated the ability of two immunizations with functionally active
SmCB1 to protect mice against a challenge infection of S. mansoni. Here we have compared a
second cysteine protease, SmCL3 that is also expressed in the S. mansoni digestive tract [16], to
SmCB1 for its capacity to induce immune responses and protection against parasite challenge.
In keeping with previous results [14] subcutaneous immunization of mice with SmCB1
induced IgG antibody responses (titres >1:6400) which can be detected at 7 and 21 days after
the second immunization (Fig 3, panel A). At 7 and 14 days following the challenge infection
with 150 cercariae the antibody responses to SmCB1 were significantly (P< 0.05) boosted as
shown by ELISA performed at serum dilutions of 1:200 (Fig 3, panel B). Antibodies binding to
SmCB1 were of the IgM, IgG1, and IgG2b isotype to a titre of 1:400 whereas little or no IgE
was detected (titre of 1:25). By contrast, we did not detect any antibodies to SmCL3 at 7 or 21
days after two immunizations. Although, antibodies to SmCL3 were detected following para-
site challenge, these were of very low titre and markedly lower than those elicited by SmCB1
(Fig 3, panel B).
To examine early immune responses in the skin of immunized and challenged mice, EC
were removed two days after the challenge infection, incubated in the presence or absence of
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
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SmCB1 and SmCL3 and secretion of the cytokine measured. Epidermal cells from control or
SmCB1- or SmCL3-immunized mice did not release detectable levels of IL-1, IL-12, or IL-25
following stimulation in culture for 72 h with 0 or 20 μg/ml immunogen. However, both
Fig 2. Overview of vaccine schedule using combination vaccine in mice and hamsters. Schedule show regime of vaccine delivery and challenge
infection with schistosome cercariae. Time-points of tissue sampling and parasitological analysis are also shown.
https://doi.org/10.1371/journal.pntd.0005443.g002
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unstimulated and immunogen-stimulated EC from the test mice did release detectable levels
of TSLP with levels produced by EC of SmCB1-immunized mice significantly (P< 0.05) lower
compared to infected controls and SmCL3-immunized mice (Fig 4A).
Fig 3. Serum antibody response to SmCB1 and SmCL3 following immunization and challenge
infection of mice. (A) Serum antibody reactivity to SmCB1 and SmCL3 was assessed by ELISA at 7 and 21
days after second immunization and 7 and 14 days following challenge infection with 150 cercariae of S.
mansoni. (B) Antibody reactivity at 7 and 21 days after second immunization and 7 and 14 days after the
challenge infection were compared at dilutions of 1:200 with each column denoting mean value for three mice
+/- SD; asterisks indicate significance (* P < 0.05) of differences.
https://doi.org/10.1371/journal.pntd.0005443.g003
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Inguinal and popliteal LNC taken from mice 4 days after infection released low but signifi-
cant (P< 0.05) levels of IL-4 in response to stimulation with SmCB1 or SmCL3 (Fig 4B) but
only SmCB1 induced significant (P< 0.005) levels of IL-17 (Fig 4C) and IFN-γ (Fig 4D). Simi-
lar cytokine responses were observed for SC taken at 7 and 14 days after the challenge infection
and stimulated with SmCB1 and SmCL3 (S2 Fig).
Fig 4. Cytokine response of SmCB1- and SmCL3- immunized mice to the immunogen. Each column represents mean +/- SD cytokine levels
in epidermal (A) and lymph node (B-D) cell cultures (three mice per group), 2 (epidermal cells, A) and 4 (LNC, B-D) days after infection. Asterisks
indicate significance (* P < 0.05, ** P < 0.005) of differences between levels of cytokines released in cultures stimulated with 0 (medium) or 20 μg/
ml immunogen.
https://doi.org/10.1371/journal.pntd.0005443.g004
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005443 March 27, 2017 10 / 21
Both SmCB1 and SmCL3 vaccine antigens induced highly significant (P< 0.005) reduction
in total worm burdens (54.2% and 65.4%, respectively) that was reflected in comparable reduc-
tion in both male and female worms together with a significant (P< 0.05) decrease in worm
egg counts in the liver and small intestine tissues of mice (Table 1). No significant differences
were observed between SmCB1 and SmCL3 vaccine efficacy and both immunizations also
induced highly significant (P< 0.005) increase in the percentage of dead ova compared to the
infected control mice (Fig 5).
Immunogenicity and protective capacity of S. mansoni cysteine protease
SmCL3 alone and in combination with SmCB1 and SG3PDH
Consistent with the above experiments we found that only one out of 3 mice immunized with
SmCL3 produced antibodies that bound to SmCL3 in levels significantly (P< 0.05) higher
than unimmunized 7 day infected mice. Addition of SmCB1 and SG3PDH to SmCL3 did not
influence production of anti-SmCL3 antibodies even though antibodies to SmCB1 (to a titre
higher than 1:800) were induced in mice immunized with SmCL3 + SmCB1 (Fig 6A). No
SmCL3- or SmCB1-binding IgE antibodies were detected even at 1:25-diluted serum from
naïve or immunized mice from all groups, confirming the data revealing that SmCL3 vaccine
does not induce IgE specific antibodies, and that SmCB1 is a weak IgE specific antibody
inducer, but not when incorporated with SG3PDH [14].
SC taken from non-infected or unimmunized control CD-1 mice that were infected for 7
days with S. mansoni did not release detectable levels of IL-4, IL-5, IL-13, IL-17 or IFN-γ when
Table 1. Effect of immunization with SmCB1 or SmCL3 on parasitological parameters of challenge S. mansoni infection in outbred mice seven
weeks post infection.
Infected Controls SmCB1 immunized SmCL3 immunized
Total worm burden
Mean ±SD 99.0 ± 10.7 40.8 ± 10.8 34.2 ± 4.6
P value 0.0016 0.0025
Reduction (%) 58.7 65.4
Male worm burden
Mean ±SD 56.4 ± 8.6 21.3 ± 6.2 18.2 ± 2.9
P value 0.0016 0.0025
Reduction (%) 62.2 67.7
Female worm burden
Mean ±SD 42.6 ± 4.5 19.5 ± 4.8 16.0 ± 2.1
P value 0.0016 0.0012
Reduction (%) 54.2 62.4
Liver egg counts
Mean ±SD 46166 ± 14986 27142 ± 10205 33000 ± 828
P value 0.035 0.049
Reduction (%) 41.2 28.5
Intestine egg counts
Mean ±SD 60833 ± 21646 38142 ± 13993 43428 ± 7325
P value 0.048 0.032
Reduction (%) 37.3 28.6
Mice (6–7 per group) were challenged 3 weeks after second immunization with 150 cercariae of S. mansoni and assessed for parasitological parameters
seven weeks post infection. NS = not significant, as assessed by the Mann-Whitney test (two-tailed P value). Reduction % = mean number in unimmunized
mice–mean number in cysteine peptidase- immunized mice/ mean number in unimmunized mice x 100.
https://doi.org/10.1371/journal.pntd.0005443.t001
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stimulated with SmCL3 or SmCB1. SC obtained 7 days after infection with S. mansoni from
mice that were immunized with SmCL3 alone, SmCL3 + SmCB1 or SmCL3+ SmCB1 +
SG3PDH did not release IL-5, IL-13, IL-17 or IFN-γ when stimulated with SmCL3, yet released
IL-4 in response to SmCL3 and especially SmCB1, similarly to the observation reported previ-
ously with SmCB1 and FhCL1 [14]. The SC response to SmCB1 was strikingly different from
SmCL3 as the former induced greater percent of mice responding with detectable levels of IL-
17 or IFN-γ (Fig 6B and 6C).
Fig 5. Effect of immunization with SmCB1 and SmCL3 on S. mansoni egg development. Percent immature (left box),
mature (middle box) and dead (right box) ova was assessed seven weeks after infection with 150 S. mansoni cercariae in
CD1 mice (6-8/group) that were unimmunized (left column in each box) or immunized with SmCB1 (middle column in each
box) or SmCL3 (right column in each box). P values as assessed by the Mann-Whitney test; NS = not significant.
https://doi.org/10.1371/journal.pntd.0005443.g005
Fig 6. Immunogenicity of SmCL3 alone and in combination with SmCB1 and SG3PDH. (A) Percent mice with serum IgG
antibody binding to SmCL3 or SmCB1 significantly (P < 0.05) higher than naïve and 7-day infection mice is represented by grey
and black columns, respectively (B & C). Ex vivo spleen cells from 3 mice from each group of naïve, 7-day infection, SmCL3-,
SmCL3 + SmCB1-, or SmCL3+SmCB1+ SG3PDH (Antigen Mix)-immunized mice were stimulated 7 days after infection with
S. mansoni with 20 μg/ml SmCL3 (grey columns) or SmCB1 (black columns) and spleen supernatants assayed for release of
cytokines by capture ELISA. Each column represents percent mouse SC culture releasing cytokine detectable levels, higher
than mean of naïve and controls + 2 SD.
https://doi.org/10.1371/journal.pntd.0005443.g006
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005443 March 27, 2017 12 / 21
Consistent with the first vaccine experiment reported above, CD-1mice immunized twice
subcutaneously with functionally active SmCL3 protease displayed a highly significant (P<
0.0001, Mann-Whitney) reduction in challenge worm burdens (48%) compared to the control
mice when challenged with S. mansoni cercariae three weeks after the second immunization.
The level of protection was not significantly increased when SmCL3 and SmCB1 were em-
ployed as a cocktail vaccine (reduction of 51.1% in worm burdens). However, significantly
(P = 0.0035) higher protection of 69% was observed when the vaccine was composed of
SmCL3 + SmCB1 + SG3PDH (Fig 7A). Furthermore, immunization of CD-1 mice with
SmCL3 + SmCB1 was associated with highly significant decrease in parasite egg load in liver
and small intestine (53% and 59%, respectively, P<0.0001) which was further decreased when
SG3PDH was added to the vaccine cocktail (73% and 70%, respectively, P<0.0001) (Fig 7B
and 7C).
Comparative efficacy of vaccines in outbred mice and hamsters
A third series of vaccines trials was performed to support the protective efficacy of SmCB1 and
SmCL3 and to compare this data in two laboratory outbred models, CD-1 mice and hamsters.
The focus of the previous experiments was to compare the immunogenicity of SmCB1 and
SmCL3. The focus in the third experiment was to compare the adjuvant effects of SmCB1
and SmCL3 on responses to SG3PDH. Accordingly, we analyzed the antibody response to
SG3PDH in the presence of the peptidase in the vaccine cocktail (Fig 8A and 8B). Antibody
reactivity to SG3PDH was observed in challenged mice immunized with SmCB1+ SG3PDH,
SmCL3+ SG3PDH or SmCB1+SmCL3+ SG3PDH and was significantly (P< 0.005) higher
than non-immunized mice (Fig 8A). The adjuvant effect of SmCB1 and SmCB1 + SmCL3 on
mouse humoral reactivity to SG3PDH was characterized by the production of substantial
Fig 7. Effect of immunization with SmCL3 alone or with SmCB and SG3PDH on parasitological parameters of
challenge S. mansoni infection in outbred mice. Mice (10 per group) unimmunized (Group 1), immunized with SmCL3
(Group 2), SmCL3 + SmCB1 (Group 3) or SmCL3 + SmCB1+ SG3PDH (Group 4) were challenged 3 weeks after second
immunization with 120 cercariae of S. mansoni and assessed for parasitological parameters 6 weeks post infection. P values as
assessed by the Mann-Whitney test (two-tailed). Reduction % = mean number in unimmunized mice–mean number in
immunized mice/ mean number in unimmunized mice x 100.
https://doi.org/10.1371/journal.pntd.0005443.g007
Protective immunity of cysteine peptidase-based schistosomiasis vaccine
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005443 March 27, 2017 13 / 21
Fig 8. Mouse serum antibody and cytokine response to SG3PDH delivered with cysteine peptidases.
Sera taken from control and immunized [SmCB1+ SG3PDH, SmCL3+ SG3PDH and SmCB1+SmCL3
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amounts of IgG1 antibodies (Fig 8B) which contrasts with our previous studies showing that
murine humoral responses to SG3PDH administered alone is limited to IgG2a and IgG2b [10,
11]. Cytokine production by SC in response to SG3PDH was characterized by the detection of
low but significant levels of IL-4, IL-5, IL-13, IL-17 and particularly IFN-γ (Fig 8C).
The combination of SmCB1 or SmCL3 with SG3PDH as a vaccine cocktail induced highly
significant (P<0.02 -<0.008) reduction in challenge worm burden in immunized CD-1 mice
(66–71%) and hamsters (51–66%) compared to unimmunized animals. A very significant
(P = 0.0006) reduction of 76% was achieved in total worm burden (reflected in both male and
female challenge worms) in mice given the vaccine formula SmCB1 + SmCL3 + SG3PDH. The
cocktail vaccine also elicited highly significant (P< 0.008) decrease (66% - 74%) in challenge
worm burden in hamsters, challenged either 4 or 6 weeks after the second immunization
(Table 2). The decrease in total egg counts in liver and intestine was less pronounced in ham-
sters compared to mice. However, SmCB1 or SmCL3 + SG3PDH and SmCB1 + SmCL3 +
SG3PDH did induce significant (P< 0.05) reduction in percentage of immature ova and
+ SG3PDH (Antigen Mix)] mice obtained 7 days after challenge S. mansoni infection were analyzed for
antibody titers (A) and isotype (B) to SG3PDH in ELISA. Spleen cells obtained at the same time point were
analyzed for cytokine responses following in vitro stimulation with 0 or 20 μg/ml SG3PDH (C). Each point or
column represents mean values +/- SD for three mice per group. Asterisks indicate significance (* P < 0.05,
** P < 0.005) of differences between immunized & infected and control-infected mice.
https://doi.org/10.1371/journal.pntd.0005443.g008
Table 2. Effects of the cysteine peptidase-based vaccine on challenge worm parasitological parameters six weeks post infection.
% Reduction in total*
Vaccine formulation Worms Eggs (liver) Eggs
(intestine)
% Reduction in immature
ova
% Reduction in mature
ova
% Increase in dead
ova**
1. CD1 mice challenged 2 weeks after last immunization with 120 cercariae
SmCB1 + SG3PDH 66.1
(0.0012)
43.4 (0.014) NS 33.1 (0.035) NS 73.2 (0.0001)
SmCL3 + SG3PDH 70.9
(0.0012)
56.7
(0.0012)
42.8 (0.035) 70.6 (0.0002) NS 81.9 (0.0004)
SmCB1 + SmCL3
+ SG3PDH
76.5
(0.0006)
61.6
(0.0006)
57.1 (0.0023) 58.7 (0.0003) NS 87.4 (0.0001)
2. Hamsters challenged 4 weeks after last immunization with 200 cercariae
SmCB1 + SG3PDH 58.1 (0.016) NS NS 28.9 (0.049) NS 81.2 (0.0001)
SmCL3 + SG3PDH 53.4
(0.0079)
NS 34.5 (0.028) 44.6 (0.011) NS 80.5 (0.0001)
SmCB1 + SmCL3
+ SG3PDH
66.2
(0.0079)
30.1 (0.016) 32.6 (0.028) 27.1 (0.048) 38.7 (0.045) 82.3 (0.0001)
3. Hamsters challenged 6 weeks after last immunization with 150 cercariae
SmCB1 + SG3PDH 50.8
(0.0079)
NS NS NS NS 80.2 (0.0077)
SmCL3 + SG3PDH 62.5
(0.0079)
25.5 (0.048) 28.8 (0.043) 42.8 (0.021) NS 83.1 (0.0004)
SmCB1 + SmCL3
+ SG3PDH
74.1 (0.005) 41.3 (0.013) 32.9 (0.027) 38.5 (0.038) NS 81.5 (0.0001)
Mice (7 per group) and hamsters (5 per group) were evaluated for parasitological parameters six weeks post infection with cercariae of S. mansoni.
*Percent reduction was evaluated by the formula: % reduction = mean number in infected controls − mean number in infected, treated hosts/mean number
in infected controls × 100. P values as calculated by 2-tailed Mann-Whitney test, in brackets.
**Percent increase was evaluated by the formula: % increase = − mean number in infected, treated hosts − mean number in infected controls/mean
number in infected, treated hosts × 100. NS = not significant.
https://doi.org/10.1371/journal.pntd.0005443.t002
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highly significant (around P = 0.0001) increase of>80% in the percentage of dead ova in small
intestine of immunized as compared to unimmunized hosts (Table 2).
Discussion
There is an urgent need to develop vaccines for schistosomiasis given our almost complete
dependency on the drug praziquantel and the lack of new compounds entering the develop-
ment pipeline [4]. Peptidases, particularly those involved in the degradation of blood proteins
for nutrient, have for a long time been considered important targets at which we could direct
both drugs and vaccines [21, 22]. Cathepsin B, SmCB1, is one of the most prominent and
immunogenic peptidase secreted from the gastrodermis of schistosomes [20–22, 25]. Recently
we discovered that this enzyme could induce high levels of protection in mice against a chal-
lenge infection with cercariae of S. mansoni when delivered subcutaneously as a functionally
active recombinant form without adjuvant [14, 15]. The protection afforded by active cathep-
sin B was suggested to be partly due to its ability to activate components of the innate immune
system in a non-specific manner as the cysteine peptidase papain from plants [11, 13] and the
papain-like cathepsin L1, FhCL1, of the related trematode Fasciola hepatica [14, 15], also had
the capacity to induce protection against S. mansoni. Notwithstanding, we felt it judicious to
pursue SmCB1 as a protective vaccine molecule rather than these other peptidases for schisto-
somiasis because it was derived from the parasite itself. Furthermore, we found that inactive
SmCB1 also possesses protective properties, albeit lower than active cathepsin B [14], and
recently Ricciardi et al. [26] showed that SmCB1 formulated in Montanide ISA 720 VG
induced elicited high-level protection against S. mansoni. In the present study, we pursued
another schistosome peptidase that was recently shown to be located in the schistosome diges-
tive tract, S. mansoni cathepsin L3 (SmCL3) [16], and investigated its immunogenicity and
protective properties alone and in combination with the cathepsin B peptidases without adju-
vant. To do this we produced a functionally active SmCL3 protease in the methylotrophic
yeast Pichia pastoris similar to the manner in which we produced SmCB1 [20].
To our surprise, we found that SmCL3 induced weaker humoral immune responses when
administered subcutaneously to outbred CD-1 mice compared to SmCB1 despite that SmCL3
displays only 46% identity with mouse cathepsin L [16]. Two immunizations of SmCL3 elicited
no detectable IgG antibody responses to the immunogen at 7 and 21 days after secondary
immunization, reflecting an inability to induce T helper cells and release of cytokines that pro-
mote antibody production. The SmCL3 poor immunogenicity could be ascribed to its uniquely
broad proteolytic substrate specificity [16]. In support, the inability of SmCL3 to strongly acti-
vate the cellular arm of the host immune system was also observed in vitro whereby ex vivo-
stimulated SC released low, albeit detectable, levels of IL-4. By contrast, SmCB1 induced a
greater level of cytokine responses from LNC and SC and these were not limited to the type 2
cytokine IL-4 as IL-17 and IFN-γ were also detected. Furthermore, IgM, IgG1, IgG2a and
IgG2b antibodies to SmCB1 were produced in vivo at 7 and 21 days after secondary immuniza-
tion. Although a low level of anti-SmCL3 antibody was detected following a challenge infection
of vaccinated mice these were far lower than those observed for SmCB1, suggesting a more
prominent infection-associated anamnestic response for the latter peptidase which is supported
by it well-known immunogenicity in experimental and natural infection [27]. However, both
peptidases stimulated detectable levels of TSLP from EC cells in vitro that suggests a role for
this master cytokine of type 2 immune responses [28, 29] in initiating protective responses. Our
previous studies have shown that delivery of TSLP to mice induced type-2 related protective
immune responses against S. mansoni challenge infection [11], which could have involved the
recruitment and activation of eosinophils, basophils, and mast cells [29–36].
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Despite the lower immune responses induced by SmCL3 compared to SmCB1, the pepti-
dase elicited a highly significant (P< 0.005) reduction (~65%) in challenge S. mansoni worm
burden, and not significantly different from the protection levels induced by SmCB1 (59%). In
this trial immunization with either S. mansoni cysteine peptidase was associated with low but
significant (P< 0.05) decreases in parasite eggs within the intestine and liver in comparison to
the infected controls, and a very significant effect (P< 0.005) on the maturation and viability
of eggs in these tissues observed. This is relevant as dead ova are likely unable to elicit inflam-
matory responses in the host or participate in transmission of the infection [24]. The data may
indicate that cysteine peptidase-induced immune responses that may not only act directly on
the female worm reproductive system via reducing fecundity but also interfere somehow in
the development of the embryo within the egg. Perhaps the latter effect is due a blocking of the
ability of female worms to digest blood proteins effectively and, consequently, acquire suffi-
cient amino acids for egg protein synthesis.
In repeat experiments, an analysis of immune responses to SmCL3 delivered in combina-
tion with SmCB1 or SG3PDH, confirmed its lack of ability to elicit production of considerable
levels of SmCL3-specific antibodies (IgG1 antibodies were observed but only to a titer of 1:25)
and to stimulate SC ex vivo barely detectable levels of IL-4. Despite this apparent lack of immu-
nogenicity significant (48%, P< 0.0005) reduction in total worm burden and parasite egg load
in liver and small intestine at three weeks after infection was observed. However, the protective
potential of SmCL3 was not increased upon inclusion of SmCB1 to the vaccine. Likewise, we
previously found that a combination of FhCL1 and SmCB1 peptidases did not elicit the addi-
tive protective effect of each peptidase given alone [14]. However, inclusion of SG3PDH with
the SmCB1 and SmCL3 cysteine peptidases increased protection to>69% in S. mansoni worm
burden and improved on the vaccine’s capacity to reduce egg loads in the liver and small intes-
tine tissues. The enhanced protection could be associated with immune responses directed
against lung-stage larvae that express SG3PDH on their surface and also release it as a compo-
nent of their ESP [18, 19].
In a final series of vaccine trials (shown in Table 2) we set out to support the data obtained
in previous tests but also to compare the protective potential in mice and hamsters. Further-
more, in the case of hamsters, the time period between the second immunization and challenge
infection with S. mansoni cercariae was compared at four and six weeks. These studies were
also motivated by the recently published discussion article by Wilson and colleagues [37] who
argued that the mouse model may give spurious vaccine results due to physiological features of
the murine pulmonary system (non-specific, inflammation-associated leakiness of the lung
vasculature that drive parasites into the alveoli) [37]. Our previous vaccine trials with cysteine
peptidases [11, 14, 15] were cited as an example, if not evidence, of a vaccine that could in-
duce these non-specific responses. In these trials in mice, antibody and cytokine responses to
SG3PDH were observed and revealed that, (a) IgG responses to SG3PDH was comparable in
all three groups combination vaccines, SmCL3 + SG3PDH, SmCB1 + SG3PDH and SmCB1 +
SmCL3 + SG3PDH and comprised IgG1 and IgG2 isotypes, and (b) type 1, 2 and 17 cytokine
were detected in all groups indicating the induction of mixed Th1/Th2 responses, although the
group given SmCB1 + SmCL3 + SG3PDH exhibited a more skewed Th1/Th17 response to
SG3PDH (Fig 7). These responses are similar to the profile observed when SG3PDH was co-
administered with the cytokines TSLP, IL-25 and IL-33 [11]. The protection reported by Ric-
ciardi et al. [26] using Montanide-formulated SmCB1 also was attributed to a mixed Th1/
Th2/Th17 response. Most importantly, the data revealed that combining SmCB1 or SmCL3
with SG3PDH provided an adjuvant-like effect that was accompanied by highly significant
(P< 0.05-<0.005) reduction in challenge worm and worm egg burden and the proportion of
immature ova (Table 2), Consistent with the observed potent antibody and cellular immune
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responses to SG3PDH, the protection level achieved with the complete vaccine formula,
SmCB1 + SmCL3 + SG3PDH, was remarkably high, ~76% in total worm burden. High levels
of protection were also observed in vaccinated hamsters with SmCB1 or SmCL1 and SG3PDH
(50–62%), with particularly high reductions of 66% and 74.1% in total worm burden recorded
in hamsters challenged four and six weeks after the second immunization with SmCB1 +
SmCL3 + SG3PDH. These protective anti-worm data were accompanied with consistent,
reproducible, and highly significant increases in the number of dead ova within the small
intestine.
It has been several decades since the World Health Organization (WHO) proposed a
threshold level of 40% reduction in challenge worm burden in an experimental host for spon-
soring a schistosome vaccine for pre-clinical trials and still very few molecular vaccines have
passed this relatively-low bar [3, 37]. Here we provide further evidence for the protective
capacity of cysteine peptidases when administered subcutaneously in functionally active form.
The mechanism by which cysteine peptidase elicit protective responses is still not fully under-
stood, especially considering their low immunogenicity when administered in this fashion
(particularly SmCL3, as observed in this study), but we suggest that a contributing factor is
the provocation of a Th2 or Th1/Th2/Th17 immune response by activating innate immune
responses. Further work is required to explore whether the mechanism activation of immune
responses by cysteine proteases and whether this can be enhanced by other protective surface
or ESP antigens in order to promote greater anti-parasite activity as we have shown in this
study with SG3PDH. Although we have not addressed all the suggestions of Wilson et al. [37]
to test their assertions that the mouse model is one that predisposes towards spurious or mis-
leading vaccine results, we have at least demonstrated that protection can be induced in
another rodent model hamster, and that protection levels are retained even when he challenge
infection is given six weeks after the final immunization. It must be also emphasized that our
vaccine formulation is delivered without adjuvant and, therefore, the likelihood of non-specific
physiological factors being involved in protection in lessened. We believe that the multiple
trial data in the present study justifies the candidacy of the cysteine peptidase-based vaccine
for funding to support independent trials in mice and non-human primates and, if shown
promise, should be positioned in a development pipeline for human Phase 1 trials.
Supporting information
S1 Fig. SmCB1 (A) and SmCL3 (B) recombinant proteins were produced in Queen’s Univer-
sity Belfast using the yeast Pichia pastoris as the expression system. The double band of SmCB1
and the low band of SmCL3 are evidence of proteolytic processing of the zymogen enzymes to
mature form during the isolation procedure. (C) The proteases were demonstrated to be func-
tionally active with SmCB1 and SmCL3 having a specificity activity of 30,000 and 60,000 rfu/
μg over 4 mins at 37˚C against the fluorogenic peptide substrate Z-Phe-Ala-NHMec (see refer-
ence 20). (D) Purified rSG3PDH, prepared at Cairo University, migrated at 40 kDa. Enzymatic
analysis determined that the purified recombinant protein possesses distinct GAPDH activity
as assessed by the Glyceraldehyde 3 Phosphate Dehydrogenase Activity Colorimetric Assay Kit
(ab204732, Abcam, Cambridge, MA). The specific activity was approximately 30% of that
observed for control rabbit GAPDH.
(PPTX)
S2 Fig. Typical cytokine response of SmCB1- and SmCL3- immunized mice to the immu-
nogen 7 or 14 days after challenge infection. Each column represents mean cytokine levels
+/- SD released by spleen cells of three mice per group 14 days after infection. Asterisks indi-
cate significance ( P< 0.05,  P< 0.005) of differences between levels of cytokines released
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in cultures stimulated with 0 (medium) or 20 μg/ml immunogen.
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